Martine Rothblatt, who serves as chairperson and chief executive officer of United Therapeutics Corp (NASDAQ: UTHR), completed a set of stock sales on April 16, 2026, totaling $5.48 million. The disposition was executed in several tranches with sale prices ranging from $573.9595 to $581.3325 per share.
The detailed breakdown of the transactions is as follows:
- 400 shares sold at $573.9595
- 1,800 shares sold at $574.7892
- 930 shares sold at $575.9883
- 2,048 shares sold at $577.0326
- 2,027 shares sold at $578.0501
- 1,750 shares sold at $579.3649
- 385 shares sold at $579.8397
- 160 shares sold at $581.3325
In addition to the share sales, Rothblatt exercised stock options on the same date to acquire 9,500 shares at an exercise price of $146.03 per share, representing a total outlay of $1387285.
All of these transactions were carried out pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025. According to the plan’s disclosure, it permits the exercise of 1,734,410 stock options that either expire on March 17, 2027, or remain exercisable until December 31, 2026.
Following the April 16 activity, Rothblatt’s direct ownership in United Therapeutics stands at 40,513 shares. Indirect holdings include 166 shares held by a spouse and blocks of shares held in trusts: 324,443; 258,117; 45,596; and 10,962, respectively.
United Therapeutics has also drawn notable analyst attention in recent days after reporting earnings and revenue results. Raymond James initiated coverage on the company with an Outperform rating and a price target of $700. That firm’s view includes an expectation that Tyvaso, indicated for the treatment of idiopathic pulmonary fibrosis (IPF), could reach more than $5 billion in peak sales.
Regulatory progress for a subsidiary program was also highlighted. The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to miroliverELAP, an investigational liver assist device developed by United Therapeutics’ subsidiary Miromatrix Medical Inc.
Following recent trial data, multiple brokerages adjusted their price targets for United Therapeutics. H.C. Wainwright raised its target to $660 from $600 and maintained a Buy rating, citing promising results from the TETON-1 trial for Tyvaso in IPF. BofA Securities lifted its price target to $626 from $569, noting favorable Phase 3 TETON-1 trial data. Jefferies increased its price target to $733 from $668, and revised its estimated probabilities of success for Tyvaso to 95% in IPF and 70% in progressive pulmonary fibrosis.
Taken together, the insider transactions and the raft of analyst updates mark a busy period for United Therapeutics, combining executive portfolio adjustments with intensified market scrutiny of the company’s therapeutic prospects.